Skip to main content
TheraVet SA logo

TheraVet SA — Investor Relations & Filings

Ticker · ALVET ISIN · BE0974387194 LEI · 984500804EBR3F1EFF71 BR Manufacturing
Open in API
Filings indexed 239 across all filing types
Latest filing 2023-04-25 Earnings Release
Country BE Belgium
Listing BR ALVET

About TheraVet SA

https://www.egeiro.com/

TheraVet SA is a veterinary biotechnology company specializing in the development and commercialization of treatments for osteoarticular diseases in companion animals. The company focuses on creating a portfolio of pharmaceutical products and solutions designed to manage bone and joint conditions, such as osteoarthritis. Its primary objective is to provide innovative therapeutic options to improve the mobility and quality of life for pets.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 98% confidence The document is titled "TheraVet publie ses résultats annuels pour l'exercice 2022..." and explicitly announces "ses résultats annuels pour l'exercice 2022." It contains a detailed table of financial results for the year ended December 31, 2022, and compares them to 2021. This strongly indicates an Earnings Release (ER) or a summary preceding the full Annual Report (10-K). However, it also mentions the Annual Report 2022 "sera publié le 25 avril 2023" (will be published on April 25, 2023) and that the auditor issued an unmodified report on the annual accounts. Since this document provides the key financial highlights and management commentary for the full year, it functions as the primary Earnings Release (ER) for the annual period, even though it references the forthcoming full 10-K/Annual Report. Furthermore, it announces materials for the upcoming AGM. Given the focus on the *release* of the annual results (key figures provided) rather than being the comprehensive 10-K itself, ER is the most appropriate classification for this press release format. It is not a Report Publication Announcement (RPA) because it contains substantial financial data, not just a notice of publication. FY 2022
2023-04-25 French
Rapports financiers et d'audit annuels / Rapport financier annuel
Annual Report Classification · 100% confidence The document is titled 'RAPPORT FINANCIER ANNUEL 2022' (Annual Financial Report 2022) and contains a comprehensive summary of company activities, governance, risk factors, and full financial statements (balance sheet, income statement, cash flow). It is clearly the primary annual reporting document for the company TheraVet SA, fitting the definition of an Annual Report (10-K). FY 2022
2023-04-25 French
Inside Information / News release on accounts, results
Earnings Release Classification · 95% confidence The document explicitly announces the 'Full-Year 2022 Financial Results' and includes detailed financial tables comparing 2022 and 2021 results, which strongly suggests an Earnings Release (ER) or an Interim/Quarterly Report (IR). However, the text also mentions the '2022 annual report ended December 31, 2022 will be published on April 25, 2023' and that the statutory auditor issued an unmodified report on the annual accounts. Since the document contains the full financial highlights and detailed commentary (Management's Discussion and Analysis style) for the full year, it functions as the primary release of the annual performance data. Given the comprehensive nature of the financial data presented (Revenue, EBITDA, Net Profit/loss, Balance Sheet items like Net Cash) and the detailed operational commentary, it is more than just a brief 'Earnings Release' (ER). It is the comprehensive annual disclosure. However, it is not the full 10-K filing itself, as it references the upcoming publication of the '2022 annual report'. The document is a press release announcing the results and providing the key figures and management discussion, which aligns best with the definition of an Earnings Release (ER). Furthermore, it announces preparatory documents for the AGM, but the core content is the annual results announcement. If the document were the full annual report, it would be classified as 10-K. Since it is the press release announcing the results, ER is the most appropriate code, despite the length, as it precedes the formal 10-K filing. FY 2022
2023-04-25 English
Inside Information / Other news releases
Environmental & Social Information Classification · 99% confidence The document is a press release dated April 06, 2023, announcing the launch of TheraVet's Osteosarcoma Reference Centers program and a new dedicated website. It details a new business initiative and operational update rather than reporting financial results (ER/IR), providing formal audit information (AR), announcing management changes (MANG), or disclosing insider trading (DIRS). This type of announcement, which details a significant operational development or strategic move, does not fit neatly into the specific financial filing codes like 10-K, IR, or CAP. Since it is a general corporate announcement that doesn't match the other specific categories (like AGM, DIV, DVA, etc.), the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general category for miscellaneous corporate announcements not covered elsewhere.
2023-04-06 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated April 6, 2023, announcing the launch of TheraVet's Reference Center program for canine osteosarcoma and a related dedicated website. It details business strategy, product information (BIOCERA-VET), and contact information for investors and press. This type of announcement, which communicates significant operational or strategic updates outside of mandatory periodic financial filings (like 10-K or IR), typically falls under general regulatory announcements or news releases. Since it is not a formal financial report (10-K, IR, ER, MRQ), a specific management discussion (MDA), or a capital event (CAP, SHA), the most appropriate general category for a significant, non-financial-specific corporate update released to the public and investors is 'Regulatory Filings' (RNS), which serves as a broad category for miscellaneous official announcements not covered elsewhere.
2023-04-06 French
Inside Information / Other news releases
Earnings Release Classification · 95% confidence The document is titled "TheraVet updates on its development and portfolio strategy" and provides a detailed narrative update on R&D programs, strategic positioning, clinical studies, and pipeline progress as of March 28, 2023. It includes quotes from management and outlines future product launches and study adjustments. This content structure—a comprehensive, narrative update on business operations, strategy, and pipeline progress, often released outside of mandatory quarterly/annual filings—is characteristic of an Investor Presentation (IP) or a detailed Management Discussion and Analysis (MDA). Since it is a strategic update rather than a formal financial statement (like 10-K or IR) or a brief earnings highlight (ER), and it is presented as a strategic overview for investors, 'Investor Presentation' (IP) is the most fitting category. It is not a short announcement of a report (RPA/RNS), as the document itself contains substantial strategic detail. H1 2023
2023-03-28 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.